TIDES Europe 2022
KACTUS will be at TIDES Vienna on November 16-18th: Chat with us to see how we...
Nov 09, 2022
October Products
KACTUS has developed the following new products to facilitate the latest innovations in drug development....
Oct 28, 2022
Targeting Axl-GAS6—a new option for tumor therapy
Tumor drug resistance is a major problem limiting the clinical efficacy of therapeutic drugs. Recently,...
Sep 12, 2022
Potential Immunotherapy Target TM4SF1
TM4SF1 (Transmembrane 4L six family member 1) is a member of the TM4SF subfamily in...
Sep 05, 2022
CDH17: A Safe CAR-T Target for Treatment of Solid Tumors
Chimeric antigen receptor T cell (CAR-T) therapy has been successful in the field of hematological...
Jul 19, 2022
GDF15-GFRAL breaks into the new drug track
A variety of metabolic diseases that plague today's society, such as obesity, diabetes, cancer, etc.,...
Jul 12, 2022
The culprit of cancer metastasis - uPAR-uPA
Tumor invasion and metastasis are key risk factors for tumor recurrence and patient death. Tumor...
Jul 07, 2022